Literature DB >> 31358436

Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents.

Olivia S Kowalczyk1, Ana I Cubillo2, Anna Smith3, Nadia Barrett3, Vincent Giampietro4, Michael Brammer4, Andrew Simmons5, Katya Rubia3.   

Abstract

Problems with sustained attention are a key clinical feature of Attention Deficit/Hyperactivity Disorder (ADHD) which also manifests in poor performance and abnormal fronto-striato-parietal activation during sustained attention. Methylphenidate and atomoxetine improve attention functions and upregulate abnormal fronto-cortical activation during executive function tasks in ADHD patients. Despite this, no functional Magnetic Resonance Imaging (fMRI) study has compared the effects of methylphenidate and atomoxetine on the neurofunctional substrates of sustained attention in ADHD. This randomised, double-blind, placebo-controlled, cross-over study investigated the comparative normalisation effects of methylphenidate and atomoxetine on fMRI correlates and performance in 14 ADHD adolescents relative to 27 age-matched healthy controls during a parametric sustained attention/vigilance task with progressively increasing load of sustained attention. ADHD patients were scanned three times under a single clinical dose of either methylphenidate, atomoxetine, or placebo in pseudo-randomised order. Healthy controls were scanned once and compared to patients under each drug condition to test for potential drug-normalisation effects. Relative to controls, ADHD boys under placebo were impaired in performance and had underactivation in predominantly right-hemispheric fronto-parietal, and striato-thalamic regions. Both drugs normalised all underactivations, while only methylphenidate improved performance deficits. Within patients, methylphenidate had a drug-specific effect of upregulating left ventrolateral prefrontal/superior temporal activation relative to placebo and atomoxetine, while both drugs increased activation of right middle/superior temporal cortex, posterior cingulate, and precuneus relative to placebo. The study shows shared normalisation effects of methylphenidate and atomoxetine on fronto-striato-thalamo-parietal dysfunction in ADHD during sustained attention but a drug-specific upregulation effects of methylphenidate on ventral fronto-temporal regions.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Atomoxetine; Attention deficit hyperactivity disorder; Functional magnetic resonance imaging; Methylphenidate; Sustained attention; Vigilance

Year:  2019        PMID: 31358436     DOI: 10.1016/j.euroneuro.2019.07.139

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  10 in total

1.  A Longitudinal Study of Resting-State Connectivity and Response to Psychostimulant Treatment in ADHD.

Authors:  Luke J Norman; Gustavo Sudre; Marine Bouyssi-Kobar; Wendy Sharp; Philip Shaw
Journal:  Am J Psychiatry       Date:  2021-06-04       Impact factor: 19.242

2.  Dorsal-to-ventral imbalance in the superior longitudinal fasciculus mediates methylphenidate's effect on beta oscillations in ADHD.

Authors:  Cecilia Mazzetti; Christienne Gonzales Damatac; Emma Sprooten; Niels Ter Huurne; Jan K Buitelaar; Ole Jensen
Journal:  Psychophysiology       Date:  2022-02-14       Impact factor: 4.348

3.  Adult attention-deficit/hyperactivity disorder is associated with reduced norepinephrine transporter availability in right attention networks: a (S,S)-O-[11C]methylreboxetine positron emission tomography study.

Authors:  Christine Ulke; Michael Rullmann; Jue Huang; Julia Luthardt; Georg-Alexander Becker; Marianne Patt; Philipp M Meyer; Solveig Tiepolt; Swen Hesse; Osama Sabri; Maria Strauß
Journal:  Transl Psychiatry       Date:  2019-11-15       Impact factor: 6.222

4.  A mixed herbal extract as an adjunctive therapy for attention deficit hyperactivity disorder: A randomized placebo-controlled trial.

Authors:  Sujin Bae; Sunhye Park; Doug Hyun Han
Journal:  Integr Med Res       Date:  2021-01-16

5.  A Retrospective Comparative Study in Patients With Cocaine Use Disorder Comorbid With Attention Deficit Hyperactivity Disorder Undergoing an rTMS Protocol Treatment.

Authors:  Stefano Cardullo; Luis J Gómez Pérez; Diego Cuppone; Michela Sarlo; Nicola Cellini; Alberto Terraneo; Luigi Gallimberti; Graziella Madeo
Journal:  Front Psychiatry       Date:  2021-03-25       Impact factor: 4.157

6.  Correlation between brain function and ADHD symptom changes in children with ADHD following a few-foods diet: an open-label intervention trial.

Authors:  Saartje Hontelez; Tim Stobernack; Lidy M Pelsser; Peter van Baarlen; Klaas Frankena; Martine M Groefsema; Michiel Kleerebezem; Rob Rodrigues Pereira; Elbrich M Postma; Paul A M Smeets; Marion A Stopyra; Marcel P Zwiers; Esther Aarts
Journal:  Sci Rep       Date:  2021-11-12       Impact factor: 4.379

Review 7.  The Mechanism, Clinical Efficacy, Safety, and Dosage Regimen of Atomoxetine for ADHD Therapy in Children: A Narrative Review.

Authors:  Di Fu; Dan-Dan Wu; Hong-Li Guo; Ya-Hui Hu; Ying Xia; Xing Ji; Wei-Rong Fang; Yun-Man Li; Jing Xu; Feng Chen; Qian-Qi Liu
Journal:  Front Psychiatry       Date:  2022-02-09       Impact factor: 4.157

8.  Methylphenidate remediates aberrant brain network dynamics in children with attention-deficit/hyperactivity disorder: A randomized controlled trial.

Authors:  Yoshifumi Mizuno; Weidong Cai; Kaustubh Supekar; Kai Makita; Shinichiro Takiguchi; Akemi Tomoda; Vinod Menon
Journal:  Neuroimage       Date:  2022-05-28       Impact factor: 7.400

9.  Shared and Unique Effects of Long-Term Administration of Methylphenidate and Atomoxetine on Degree Centrality in Medication-Naïve Children With Attention-Deficit/Hyperactive Disorder.

Authors:  Zhao Fu; Jing Yuan; Xuyao Pei; Kangfuxi Zhang; Chenyang Xu; Na Hu; Rao Xie; Yilu Zhao; Yufeng Wang; Li Yang; Qingjiu Cao
Journal:  Int J Neuropsychopharmacol       Date:  2022-09-28       Impact factor: 5.678

Review 10.  Treatment biomarkers for ADHD: Taking stock and moving forward.

Authors:  Giorgia Michelini; Luke J Norman; Philip Shaw; Sandra K Loo
Journal:  Transl Psychiatry       Date:  2022-10-12       Impact factor: 7.989

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.